Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: 26 | History Defined

Is Harmony Biosciences Holdings Inc. (HRMY) a Biotech Stock to Consider?

Harmony Biosciences’ (HRMY) recently released growth plans and pipeline advancements have showcased the company’s dedication towards being a top contender in the highly contested biotech market. So, should investors looking to capitalize on the industry’s prospects consider investing in HRMY? Read more….

StockNews.com

AstraZeneca ‘very disappointed’ over axed £450m Liverpool vaccine project

As drugmaker reports 38% jump in profits, CEO denies tension with UK government after Speke plant decision

The Guardian - UK

Drug firm GSK delivers a syringe full of crowd-pleasers

Pharmaceuticals company’s higher dividend, upgrade to revenues and share buyback suggest its drugs pipeline is flowing nicely

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soar

Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration

The Guardian - UK

AstraZeneca’s U-turn on £450m Speke expansion ‘deeply disappointing’, says minister

Chris Bryant says reduction of government support was linked to change in drugmaker’s proposed investment

The Guardian - UK

AstraZeneca’s £450m Speke U-turn looks terrible for a pro-growth government

It seems bizarre that ministers and UK’s largest company cannot complete investment in vital life sciences sector

The Guardian - UK

AstraZeneca axes £450m vaccine plant in Liverpool, blaming state funding cut

Days after Rachel Reeves highlighted life sciences as UK strength, firm decides against site expansion

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Suspected drug deaths in Scotland down by 10 per cent, latest figures show

Suspected drugs deaths have fallen by 10 per cent in the latest quarterly data, with drug-related attendances at A&E seeing a similar decrease.

The National (Scotland)

Vivek Ramaswamy To Run For Ohio Governor In 2026

Vivek Ramaswamy, with support from JD Vance's team, gears up for the 2026 Ohio gubernatorial race in a competitive GOP landscape.

Top News

Wegovy maker Novo Nordisk rebuked by watchdog over failure to disclose payments to UK health groups

Danish drug giant found to have failed to accurately report spending even after admitting to errors

The Guardian - UK

Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.

Kiplinger

Sackler family to pay $6.5 billion for their role in ‘fueling’ opioid epidemic which has killed hundreds of thousands

Sackler family, who owned pharmaceutical company Purdue Pharma, will no longer be in control of the company or permitted to sell opioids if the new settlement plan is approved

The Independent UK

Purdue Pharma and owners to pay $7.4 billion in settlement to lawsuits over the toll of OxyContin

Members of the Sackler family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion to settle lawsuits over the toll of the powerful prescription painkiller

The Independent UK

Sacklers, Purdue To Pay $7.4 Bn Over Opioid Crisis

Several US states have reached a $7.4 billion settlement with the Sackler family and their pharmaceutical company Purdue over the opioid crisis that has ravaged the lives of millions of Americans, officials said Thursday.

International Business Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US

Purdue Pharma and Sacklers reach new $7.4bn settlement over opioids crisis

Settlement resolves thousands of lawsuits alleging Oxycontin caused addiction crisis

International Business Times UK

'It's Out of Control': UnitedHealth Group and Peers Charged Americans 1000% More for Drugs

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

Kiplinger

Medicare Price Negotiations To Continue Under the Trump Administration

The Centers for Medicare & Medicaid Services plans to negotiate the prices for 15 new drugs, although it says its seeking "greater transparency" in price talks.

Latin Times

UnitedHealth Is Price Gouging Cancer Patients by Overcharging 'Thousands of Percent' for Live-Saving Meds, Pocketing Extra Billions: Feds

The UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases the cost of such medication exponentially.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Niche Biotech Stocks Redefining Innovation

The biotech market offers great investment potential due to innovative advancements in genetic profiling, biologics, CRISPR technology, and rare disease treatments driving strong demand and growth. Therefore, investing in strong biotech stocks like Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR) could be wise. Read on.

The Guardian - UK

At last, Britain has a legal drug consumption room – thanks to one man’s civil disobedience

Former heroin addict Peter Krykant set up a safe consumption van during Covid, at great personal cost. But his sacrifice paved the way for real change, says Birkbeck’s Kojo Koram

Mic

Bayer Hit with $100 Million Verdict Over Toxic PCB Exposure

Bayer AG faces a $100 million jury verdict over PCB exposure at a Seattle school amid ongoing legal challenges related to toxic chemicals.

StockNews.com

Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space?

Aurinia Pharmaceuticals (AUPH) released its third-quarter results, reporting solid revenue growth and robust cash flow from operations. Solid demand for its product offerings, restructuring strategies, and sound financials remain key drivers of the company’s growth and success. So, let’s analyze whether AUPH is a buy today. Read more to find…

The National (Scotland)

‘Positive feedback’ from first users of Glasgow's drugs consumption room

The UK’s first safer drug consumption room has had good uptake and “positive feedback” from users since opening in Glasgow, a minister has…

Evening Standard

‘Positive feedback’ from first users of safer drugs consumption room – minister

Neil Gray said the success of the Thistle Centre would be measured if there are fewer drug deaths and ‘harm reduction’.

The Independent UK

J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by purchasing Intra-Cellular Therapies

1 … 25 26 27 28

People

Lars Fruergaard Jørgensen

18 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.